Asset Details
Do you wish to reserve the book?
New-generation Myval transcatheter heart valve in severe aortic stenosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
New-generation Myval transcatheter heart valve in severe aortic stenosis
Do you wish to request the book?
New-generation Myval transcatheter heart valve in severe aortic stenosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
New-generation Myval transcatheter heart valve in severe aortic stenosis
2024
Overview
Transcatheter aortic valve implantation (TAVI) has become a well established treatment option in patients with severe aortic stenosis, regardless of the surgical risk spectrum. 1,2 The refinement of techniques and broadening of indications have meant complication rates—including death, strokes, and vascular complications—have drastically decreased over time, 1,2 without serious concerns regarding transcatheter heart valve (THV) durability. 3 The current focus lies on a tailored approach, aiming to offer each patient the most suitable THV based on their specific anatomy and ensuring optimal haemodynamic performances after the index procedure and potential for repeatability in patients with increased longevity. The LANDMARK trial establishes the non-inferiority of Myval compared with contemporary THVs (25% vs 27%; risk difference –2·3% [one-sided upper 95% CI 3·8%], p non-inferiority<0·0001) for the 30-day composite endpoint (all-cause mortality, stroke, major bleeding, acute kidney injury, major vascular complications, moderate or severe prosthetic valve regurgitation, and permanent pacemaker implantation according to third Valve Academic Research Consortium criteria). The global inclusion rate of participants in this trial was only 15%, indicating high selection bias. [...]whether this new Myval THV offers long-term advantages over contemporary THVs is not yet established, especially for younger individuals, for whom repeatability and coronary access are key for lifetime management given the expected steady increase in the number of individuals with increased longevity. 9 Although commissural alignment does not seem feasible with the Sapien THV, recent promising data were published with Myval, 10 which could give it a valuable advantage for long-term outcomes.
Publisher
Elsevier Ltd,Elsevier Limited
